2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary …

…, MM Hoeper, R Badagliacca, RMF Berger… - European heart …, 2022 - academic.oup.com
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management

…, S Haworth, DD Ivy, RMF Berger - European …, 2019 - Eur Respiratory Soc
Paediatric pulmonary arterial hypertension (PAH) shares common features of adult disease,
but is associated with several additional disorders and challenges that require unique …

Pediatric pulmonary hypertension

DD Ivy, SH Abman, RJ Barst, RMF Berger… - Journal of the American …, 2013 - jacc.org
Pulmonary hypertension (PH) is a rare disease in newborns, infants, and children that is
associated with significant morbidity and mortality. In the majority of pediatric patients, PH is …

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study

…, M Beghetti, MA Gatzoulis, J Granton, RMF Berger… - Circulation, 2006 - Am Heart Assoc
Background— Eisenmenger syndrome is characterized by the development of pulmonary
arterial hypertension with consequent intracardiac right-to-left shunt and hypoxemia in …

Clinical features of paediatric pulmonary hypertension: a registry study

RMF Berger, M Beghetti, T Humpl, GE Raskob, DD Ivy… - The Lancet, 2012 - thelancet.com
Background Paediatric pulmonary hypertension, is an important cause of morbidity and
mortality, and is insufficiently characterised in children. The Tracking Outcomes and Practice in …

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

…, R Badagliacca, RMF Berger… - European …, 2023 - Eur Respiratory Soc
Guidelines summarize and evaluate available evidence, with the aim of assisting health
professionals in proposing the best management strategies for an individual patient with a given …

Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a …

…, P van der Meer, RA de Boer, RMF Berger… - European heart …, 2015 - academic.oup.com
Background Heart failure with preserved ejection fraction (HFpEF), with associated
pulmonary hypertension is an increasingly large medical problem. Phosphodiesterase (PDE)-5 …

Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry

MGJ Duffels, PM Engelfriet, RMF Berger… - International journal of …, 2007 - Elsevier
BACKGROUND: Pulmonary arterial hypertension (PAH) associated with congenital heart
disease is usually the result of a large systemic-to-pulmonary shunt, and often leads to right …

Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005

…, L Rammeloo, SAB Clur, BJM Mulder, RMF Berger - Circulation, 2011 - Am Heart Assoc
Background— Incidence and prevalence rates for pediatric pulmonary hypertension (PH) and
pulmonary arterial hypertension (PAH) are unknown. This study describes the nationwide …

Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study

…, M Beghetti, N Galič, J Granton, RMF Berger… - International journal of …, 2008 - Elsevier
BACKGROUND: Bosentan, an oral endothelin ET A /ET B receptor antagonist, improves
hemodynamics and exercise capacity in patients with Eisenmenger syndrome but longer-term …